blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3184521

EP3184521 - INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITORS, PREPARATION AND USE THEREOF [Right-click to bookmark this link]
Former [2017/26]INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF
[2021/14]
StatusNo opposition filed within time limit
Status updated on  12.08.2022
Database last updated on 01.02.2025
FormerThe patent has been granted
Status updated on  03.09.2021
FormerGrant of patent is intended
Status updated on  28.03.2021
FormerExamination is in progress
Status updated on  30.03.2019
FormerRequest for examination was made
Status updated on  26.05.2017
FormerThe international publication has been made
Status updated on  17.03.2017
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024  [2024/41]
Applicant(s)For all designated states
Shanghai Haihe Pharmaceutical Co., Ltd.
421 Newton Road
Zhangjiang Hi-tech Park
Pudong New Area
Shanghai 201203 / CN
For all designated states
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
555 Zu Chong Zhi Road
Zhangjiang
Pudong
Shanghai, 201203 / CN
[2017/26]
Inventor(s)01 / GENG, Meiyu
No.555 of Zuchongzhi Road
Zhangjiang
Pudong New Area
Shanghai 201203 / CN
02 / LIU, Lei
421 Newton Road
Zhangjiang Hi-tech Park
Pudong New Area
Shanghai 201203 / CN
03 / JIANG, Lei
421 Newton Road
Zhangjiang Hi-tech Park
Pudong New Area
Shanghai 201203 / CN
04 / HUANG, Min
No.555 of Zuchongzhi Road
Zhangjiang
Pudong New Area
Shanghai 201203 / CN
05 / ZHA, Chuantao
421 Newton Road
Zhangjiang Hi-tech Park
Pudong New Area
Shanghai 201203 / CN
06 / AI, Jing
No.555 of Zuchongzhi Road
Zhangjiang
Pudong New Area
Shanghai 201203 / CN
07 / WANG, Lei
421 Newton Road
Zhangjiang Hi-tech Park
Pudong New Area
Shanghai 201203 / CN
08 / CAO, Jianhua
421 Newton Road
Zhangjiang Hi-tech Park
Pudong New Area
Shanghai 201203 / CN
09 / DING, Jian
No.555 of Zuchongzhi Road
Zhangjiang
Pudong New Area
Shanghai 201203 / CN
 [2017/26]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2021/40]
Former [2017/26]Lenthall, Joseph, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Application number, filing date15833329.419.08.2015
[2017/26]
WO2015CN87556
Priority number, dateCN20141040946719.08.2014         Original published format: CN201410409467
CN2015107317911.02.2015         Original published format: CN201510073179
[2017/26]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016026445
Date:25.02.2016
Language:ZH
[2016/08]
Type: A1 Application with search report 
No.:EP3184521
Date:28.06.2017
Language:EN
[2017/26]
Type: B1 Patent specification 
No.:EP3184521
Date:06.10.2021
Language:EN
[2021/40]
Search report(s)International search report - published on:CN25.02.2016
(Supplementary) European search report - dispatched on:EP30.11.2017
ClassificationIPC:C07D403/12, C07D405/14, C07D231/56, C07D401/12, C07D471/04, C07D487/04, C07D401/14, C07D417/12, A61K31/496, A61K31/416, A61P35/00
[2017/26]
CPC:
C07D487/04 (EP,CN,KR,RU,US); C07D231/56 (EP,CN,KR,RU,US); C07D403/12 (EP,CN,RU,US);
A61K31/416 (EP,KR,RU,US); A61K31/496 (EP,KR,RU,US); A61P35/00 (EP,RU);
A61P35/02 (EP); A61P43/00 (EP); C07D401/12 (EP,CN,KR,RU,US);
C07D401/14 (EP,CN,KR,RU,US); C07D405/14 (EP,KR,US); C07D413/12 (KR,RU);
C07D417/12 (EP,CN,KR,US); C07D471/04 (EP,CN,KR,RU,US); C07D498/04 (EP,CN,RU,US);
C07D519/00 (EP,CN,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/26]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:INDAZOLVERBINDUNGEN ALS FGFR-KINASEHEMMER, HERSTELLUNG UND VERWENDUNG DAVON[2017/26]
English:INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITORS, PREPARATION AND USE THEREOF[2021/14]
French:COMPOSÉS INDAZOLE UTILISÉS COMME INHIBITEURS DE LA FGFR KINASE, PRÉPARATION ET UTILISATION ASSOCIÉES[2017/26]
Former [2017/26]INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF
Entry into regional phase16.03.2017Translation filed 
16.03.2017National basic fee paid 
16.03.2017Search fee paid 
16.03.2017Designation fee(s) paid 
16.03.2017Examination fee paid 
Examination procedure16.03.2017Examination requested  [2017/26]
16.03.2017Date on which the examining division has become responsible
29.06.2018Amendment by applicant (claims and/or description)
03.04.2019Despatch of a communication from the examining division (Time limit: M06)
11.10.2019Reply to a communication from the examining division
19.02.2020Despatch of a communication from the examining division (Time limit: M06)
22.09.2020Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
01.12.2020Reply to a communication from the examining division
29.03.2021Communication of intention to grant the patent
03.08.2021Fee for grant paid
03.08.2021Fee for publishing/printing paid
03.08.2021Receipt of the translation of the claim(s)
Opposition(s)07.07.2022No opposition filed within time limit [2022/37]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
01.12.2020Request for further processing filed
01.12.2020Full payment received (date of receipt of payment)
Request granted
09.12.2020Decision despatched
Fees paidRenewal fee
25.08.2017Renewal fee patent year 03
28.08.2018Renewal fee patent year 04
26.08.2019Renewal fee patent year 05
20.08.2020Renewal fee patent year 06
30.08.2021Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.08.2015
AL06.10.2021
AT06.10.2021
CY06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
MK06.10.2021
MT06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SI06.10.2021
SK06.10.2021
SM06.10.2021
TR06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
[2024/41]
Former [2024/29]HU19.08.2015
AL06.10.2021
AT06.10.2021
CY06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
MK06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SI06.10.2021
SK06.10.2021
SM06.10.2021
TR06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2024/27]HU19.08.2015
AL06.10.2021
AT06.10.2021
CY06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
MK06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SI06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2024/21]HU19.08.2015
AL06.10.2021
AT06.10.2021
CY06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SI06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2024/18]HU19.08.2015
AL06.10.2021
AT06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SI06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2023/16]AL06.10.2021
AT06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SI06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2023/01]AL06.10.2021
AT06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SI06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2022/49]AL06.10.2021
AT06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2022/35]AT06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2022/34]AT06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2022/33]AT06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
NL06.10.2021
PL06.10.2021
RS06.10.2021
SE06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2022/25]AT06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
NL06.10.2021
PL06.10.2021
RS06.10.2021
SE06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2022/24]AT06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
NL06.10.2021
PL06.10.2021
RS06.10.2021
SE06.10.2021
BG06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2022/23]AT06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
PL06.10.2021
RS06.10.2021
BG06.01.2022
PT07.02.2022
Former [2022/22]AT06.10.2021
FI06.10.2021
LT06.10.2021
RS06.10.2021
BG06.01.2022
Former [2022/21]AT06.10.2021
RS06.10.2021
BG06.01.2022
Former [2022/19]BG06.01.2022
Documents cited:Search[Y]  - P. R. GAVINE ET AL, "AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family", CANCER RESEARCH, (20120227), vol. 72, no. 8, doi:10.1158/0008-5472.CAN-11-3034, ISSN 0008-5472, pages 2045 - 2056, XP055065340 [Y] 1-10 * figure 1 *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-11-3034
 [Y]  - GUAGNANO V ET AL, "Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 54, no. 20, doi:10.1021/JM2006222, ISSN 0022-2623, (20111027), pages 7066 - 7083, (20110921), XP002689272 [Y] 1-10 * abstract *

DOI:   http://dx.doi.org/10.1021/jm2006222
 [Y]  - G. ZHAO ET AL, "A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models", MOLECULAR CANCER THERAPEUTICS, (20110907), vol. 10, no. 11, doi:10.1158/1535-7163.MCT-11-0306, ISSN 1535-7163, pages 2200 - 2210, XP055160880 [Y] 1-10 * figure 1 *

DOI:   http://dx.doi.org/10.1158/1535-7163.MCT-11-0306
International search[XY]WO03068773  (GLAXO GROUP LTD [GB], et al) [X] 1-4, 7-10 * , abstract, description, pages 6-7, and page 30, lines 6-8, and embodiments, particularly embodiment 101, abstract, description, pages 6-7, and page 30, lines 6-8, and embodiments, particularly embodiment 101 * [Y] 5-6;
 [XY]CN101962365  (AVENTIS PHARMA SA) [X] 1-4, 7-10 * , description, pages 1-2, and claim 9, description, pages 1-2, and claim 9 * [Y] 5-6;
 [Y]WO2014052563  (MERCK SHARP & DOHME [US], et al) [Y] 5-6 * , abstract, and description, page 104, solution 14 *;
 [A]US2014171405  (ZHUO JINCONG [US], et al) [A] 1-10* , the whole document *;
 [PXY]  - LIU, JIAN et al., "Design, Synthesis and Biological Evaluation of Novel FGFR Inhibitors Bearing an Indazole Scaffold", ORGANIC & BIOMOLECULAR CHEMISTRY, (20150601), vol. 13, no. 28, pages 7643 - 7654, XP055332373 [PX] 1-4, 7-10 * , particularly abstract, and tables 1 and 3 * [PY] 5-6

DOI:   http://dx.doi.org/10.1039/C5OB00778J
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.